Tandem Diabetes Care (TNDM) Accumulated Expenses (2013 - 2026)

Tandem Diabetes Care has reported Accumulated Expenses for 14 years, with the latest figure at $55.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 10.4% year-over-year to $55.7 million; the trailing twelve-month figure through Mar 2026 stood at $55.7 million (up 10.4% YoY), and the FY2025 full-year result was $70.4 million, up 287.5% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $55.7 million, down from $70.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $70.4 million in Q4 2025, with the low at $12.3 million in Q3 2024.
• Historically, Accumulated Expenses has averaged $36.3 million across 5 years, with a median of $38.7 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 656.39% — and 2023, when it slumped 70.66%.
• Tandem Diabetes Care's Accumulated Expenses stood at $38.7 million in 2022, then plunged by 67.1% to $12.7 million in 2023, then soared by 42.78% to $18.2 million in 2024, then surged by 287.5% to $70.4 million in 2025, then dropped by 20.9% to $55.7 million in 2026.
• The last three Accumulated Expenses figures came in at $55.7 million (Q1 2026), $70.4 million (Q4 2025), and $12.5 million (Q3 2025), per Business Quant data.